Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “underperform” rating reissued by equities research analysts at Wells Fargo & Co. in a research report issued on Thursday. They currently have a $19.50 price objective on the specialty pharmaceutical company’s stock. Wells Fargo & Co.’s price target points to a potential upside of 21.19% from the company’s previous close.

Several other research analysts have also commented on VRX. Rodman & Renshaw reissued a “buy” rating and set a $90.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Mizuho reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. TD Securities reissued a “hold” rating and set a $38.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Canaccord Genuity reaffirmed a “hold” rating and issued a $28.00 target price on shares of Valeant Pharmaceuticals International in a research note on Monday, July 18th. Finally, RBC Capital Markets reaffirmed a “sector perform” rating and issued a $33.00 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, July 19th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and an average target price of $42.26.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.09 on Thursday. The company’s market cap is $5.59 billion. Valeant Pharmaceuticals International has a 1-year low of $13.77 and a 1-year high of $119.87. The stock has a 50 day moving average of $22.57 and a 200 day moving average of $25.39.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a positive return on equity of 41.02% and a negative net margin of 22.17%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.49 billion. During the same period in the previous year, the firm posted $2.74 EPS. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. Analysts predict that Valeant Pharmaceuticals International will post $6.45 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Valeant Pharmaceuticals International by 185.4% in the second quarter. FMR LLC now owns 15,545,539 shares of the specialty pharmaceutical company’s stock worth $313,087,000 after buying an additional 10,099,493 shares in the last quarter. Paulson & CO. Inc. boosted its stake in Valeant Pharmaceuticals International by 44.6% in the second quarter. Paulson & CO. Inc. now owns 19,072,000 shares of the specialty pharmaceutical company’s stock worth $384,110,000 after buying an additional 5,883,900 shares in the last quarter. Hexavest Inc. boosted its stake in Valeant Pharmaceuticals International by 110.1% in the third quarter. Hexavest Inc. now owns 3,765,875 shares of the specialty pharmaceutical company’s stock worth $92,429,000 after buying an additional 1,973,087 shares in the last quarter. Okumus Fund Management Ltd. boosted its stake in Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock worth $97,901,000 after buying an additional 1,846,864 shares in the last quarter. Finally, York Capital Management Global Advisors LLC bought a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $25,944,000. 64.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.